Case number 2024-1402
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 14, 2024 | 0 | REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC. [ORDER] [nonprecedential] (0) |
| Apr 12, 2024 | 26 | ORDER Appeal Nos. 2024-1402 and 2024-1405 are dismissed. Each party shall bear iits own costs.; issuing mandate. (Per Curiam). Service as of this date by the Clerk of Court. [996970] [24-1402, 24-1405] [NL] [Entered: 04/12/2024 10:27 AM] (2) |
| Apr 9, 2024 | 24 | RESPONSE of Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc. to Doc No. [15], [15], [15]. Service: 04/09/2024 by email. [996142] [24-1402] [Deanne Mazzochi] [Entered: 04/09/2024 03:18 PM] (333) |
| Apr 9, 2024 | 25 | Confidential Corrected Defendants-Cross-Appellants' Response to Order to Show Cause filed by Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc. corresponding to Doc. No. [24]. Service: 04/09/2024 by email. [996145] [24-1402] [Deanne Mazzochi] [Entered: 04/09/2024 03:23 PM] (0) |
| Apr 3, 2024 | 23 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc., Confidential Response [21], is not in compliance with the rules of this court (see attached). Compliant document due on 04/10/2024. Service as of this date by the Clerk of Court. [994702] [JSP] [Entered: 04/03/2024 10:05 AM] (2) |
| Apr 2, 2024 | 20 | RESPONSE of Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc. to Doc No. [15], [15], [15]. Service: 04/02/2024 by email. [994644] [24-1402] [Deanne Mazzochi] [Entered: 04/02/2024 05:12 PM] (333) |
| Apr 2, 2024 | 21 | Confidential Corrected Defendants-Cross-Appellants' Response to Order to Show Cause filed by Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc. corresponding to Doc. No. [20]. Service: 04/02/2024 by email. [994645] [24-1402] This document is non-compliant. See Doc No.[23] [Deanne Mazzochi] [Entered: 04/02/2024 05:16 PM] (0) |
| Apr 2, 2024 | 22 | RESPONSE of Appellant Regeneron Pharmaceuticals, Inc. to Doc. No. [15], [15], [15]. Service: 04/02/2024 by email. [994648] [24-1402] [David Berl] [Entered: 04/02/2024 05:42 PM] (10) |
| Mar 26, 2024 | 19 | NOTICE OF NON-COMPLIANCE: The submissions of Appellant Regeneron Pharmaceuticals, Inc. and Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc., Response [18], [17], [16], are not in compliance with the rules of this court (see attached). Compliant document due on 04/02/2024. Service as of this date by the Clerk of Court. [992893] [JSP] [Entered: 03/26/2024 08:59 AM] (2) |
| Mar 25, 2024 | 16 | RESPONSE of Cross-Appellants Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. to Doc No. [15], [15], [15]. Service: 03/25/2024 by email. [992874] [24-1402] This document is non-compliant. See Doc No.[19] [Deanne Mazzochi] [Entered: 03/25/2024 06:56 PM] (333) |
| Mar 25, 2024 | 17 | Confidential Defendants-Cross-Appellants' Response to Order to Show Cause filed by Cross-Appellants Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. corresponding to Doc. No. [16]. Service: 03/25/2024 by email. [992876] [24-1402] This document is non-compliant. See Doc No.[19] [Deanne Mazzochi] [Entered: 03/25/2024 07:41 PM] (0) |
| Mar 25, 2024 | 18 | RESPONSE of Appellant Regeneron Pharmaceuticals, Inc. to Doc. No. [15], [15], [15]. Service: 03/25/2024 by email. [992879] [24-1402] This document is non-compliant. See Doc No.[19] [David Berl] [Entered: 03/25/2024 10:50 PM] (10) |
| Feb 22, 2024 | 12 | Corrected Entry of Appearance for David I. Berl; Thomas F. Fletcher; Andrew V. Trask; Shaun P. Mahaffy; Kathryn S. Kayali; Arthur J. Argall; Adam Pan; Rhochelle Krawetz as counsel for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/22/2024 by email. [985834] [24-1402] [David Berl] [Entered: 02/22/2024 03:44 PM] (3) |
| Feb 22, 2024 | 13 | Corrected Certificate of Interest for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/22/2024 by email. [985835] [24-1402] [David Berl] [Entered: 02/22/2024 03:49 PM] (4) |
| Feb 22, 2024 | 14 | Corrected Docketing Statement for the Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/22/2024 by email. [985837] [24-1402] [David Berl] [Entered: 02/22/2024 03:52 PM] (2) |
| Feb 22, 2024 | 15 | ORDER filed staying briefing schedule pending further notice of the court. Within 30 days from the date of entry of this order, the parties are directed to show cause why these appeals should not be dismissed for lack of jurisdiction. Service as of this date by the Clerk of Court. [985902] [NL] [Entered: 02/22/2024 05:02 PM] (2) |
| Feb 14, 2024 | 11 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Regeneron Pharmaceuticals, Inc., Entry of Appearance, Docketing Statement, Certificate of Interest [10], [9], [7], is not in compliance with the rules of this court (see attached). Compliant document due on 02/22/2024. Service as of this date by the Clerk of Court. [983802] [IMH] [Entered: 02/14/2024 12:16 PM] (2) |
| Feb 13, 2024 | 3 | Entry of Appearance for William A. Rakoczy; Heinz J. Salmen; Paul J. Molino; Deanne M. Mazzochi; Eric R. Hunt; Lauren M. Lesko; Neil B. McLaughlin as counsel for Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983652] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:18 PM] (2) |
| Feb 13, 2024 | 4 | Docketing Statement for the Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983653] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:22 PM] (2) |
| Feb 13, 2024 | 5 | Certificate of Interest for Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983654] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:31 PM] (5) |
| Feb 13, 2024 | 6 | Notice of Related Case Information for Cross-Appellants Biocon Biologics Inc. and Mylan Pharmaceuticals Inc.. Service: 02/13/2024 by email. [983656] [24-1402] [William Rakoczy] [Entered: 02/13/2024 10:35 PM] (5) |
| Feb 13, 2024 | 7 | Docketing Statement for the Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983658] [24-1402] This document is non-compliant. See Doc No. [11] [David Berl] [Entered: 02/13/2024 11:50 PM] (2) |
| Feb 13, 2024 | 8 | Notice of Related Case Information for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983659] [24-1402] [David Berl] [Entered: 02/13/2024 11:53 PM] (5) |
| Feb 13, 2024 | 9 | Entry of Appearance for David I. Berl; Ellen E. Oberwetter; Thomas S. Fletcher; Andrew V. Trask; Shaun P. Mahaffy; Kathryn S. Kayali; Arthur J. Argall; Adam Pan; Rhochelle Krawetz as counsel for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983660] [24-1402] This document is non-compliant. See Doc No. [11] [David Berl] [Entered: 02/13/2024 11:55 PM] (3) |
| Feb 13, 2024 | 10 | Certificate of Interest for Appellant Regeneron Pharmaceuticals, Inc.. Service: 02/13/2024 by email. [983661] [24-1402] This document is non-compliant. See Doc No. [11] [David Berl] [Entered: 02/13/2024 11:58 PM] (4) |
| Jan 30, 2024 | 1 | Appeal docketed. Received: 01/29/2024. [980267]Entry of Appearance is due on 02/13/2024. Certificate of Interest is due on 02/13/2024. Docketing Statement is due on 02/13/2024. Appellant's brief is due on 04/01/2024. [JSP] [Entered: 01/30/2024 10:16 AM] (95) |
| Jan 30, 2024 | 2 | Note to File: The following cases are consolidated: 24-1402 Lead with 24-1405 Cross-Appeal. The parties must file all documents in the lead appeal only. [980279] [24-1402, 24-1405] [JSP] [Entered: 01/30/2024 10:37 AM] (0) |
